) recently presented data from a study wherein patients suffering
from Parkinson's disease (PD) were transferred from an oral PD
medication to Neupro.
The non-interventional, observational study conducted in Germany
enrolled 76 patients. Results indicate that switching over from
oral PD medications could lead to an improvement in pre-existing
gastrointestinal (GI) symptoms.
Data from the study was presented at the annual meeting of the
American Academy of Neurology's (AAN).
In Jul 2012, UCB launched Neupro in the US to treat signs and
symptoms of advanced stage idiopathic PD and moderate-to-severe
primary restless legs syndrome (RLS). The drug was cleared by the
US Food and Drug Administration in Apr 2012. Neupro is marketed
in four and three different dosage strengths, respectively, for
the signs and symptoms of PD and RLS.
In Aug 2012, Neupro was approved in the EU for early and advanced
PD as well as RLS. In Japan, it received approval in Dec 2012 for
In 2012, Neupro recorded sales of €133 million. Currently
approved products for the treatment of PD and RLS include
UCB carries a Zacks Rank #1 (Strong Buy). We expect Cimzia,
Vimpat and Neupro to continue performing well in 2013. A few
weeks back, Vimpat was approved in the European Union (EU) as a
single loading dose option for treating patients suffering from
partial onset seizures.
Additionally, UCB announced new regulatory filings with the US
Food and Drug Administration (FDA) and the European Medicines
Agency (EMA) for two additional indications for Cimzia.
GLAXOSMITHKLINE (GSK): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.
Pharma stocks which currently look equally attractive are
Lannett Company, Inc.
WuXi Pharma Tech (Cayman) Inc.
), which carry a Zacks Rank #1.